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Abstract
The aim of this study is to investigate the blood perfusion and the inflammatory response of the myocardial infarct area after transplanting a hy-
aluronan-based scaffold (HYAFF11) with bone marrow mesenchymal stem cells (MSCs). Nine-week-old female pigs were subjected to a per-
manent left anterior descending coronary artery ligation for 4 weeks. According to the kind of the graft, the swine subjected to myocardial
infarction were divided into the HYAFF11, MSCs, HYAFF11/MSCs and untreated groups. The animals were killed 8 weeks after coronary liga-
tion. Scar perfusion, evaluated by Contrast Enhanced Ultrasound echography, was doubled in the HYAFF11/MSCs group and was comparable
with the perfusion of the healthy, non-infarcted hearts. The inflammation score of the MSCs and HYAFF11/MSCs groups was near null, reveal-
ing the role of the grafted MSCs in attenuating the cell infiltration, but not the foreign reaction strictly localized around the fibres of the scaffold.
Apart from the inflammatory response, the native tissue positively interacted with the HYAFF11/MSCs construct modifying the extracellular
matrix with a reduced presence of collagene and increased amount of proteoglycans. The border-zone cardiomyocytes also reacted favourably
to the graft as a lower degree of cellular damage was found. This study demonstrates that the transplantation in the myocardial infarct area of
autologous MSCs supported by a hyaluronan-based scaffold restores blood perfusion and almost completely abolishes the inflammatory pro-
cess following an infarction. These beneficial effects are superior to those obtained after grafting only the scaffold or MSCs, suggesting that a
synergic action was achieved using the cell-integrated polymer construct.
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Introduction
To date, the research devoted to the therapy of the myocardial infarc-
tion (MI) with mesenchymal stem/stromal cells (MSCs) had substan-
tially failed their initial purpose [1–3]. The ambitious end-point of
substituting the necrotic myocardium with a healthy native tissue is
far from being achieved. A more realistic and as much useful aim
could be the prevention of the pathological remodelling of the heart
by improving the structure of the myocardial scar [4]. It is known that
the fibrotic, post-necrotic, myocardium is represented by a thin,
weakened region that is unable to properly withstand pressure and
volume load. As a matter of fact, the intraventricular pressure pro-
gressively stretches either the scar or the neighbouring cardiac tis-
sue, leading to the dilation of the ventricular chambers and,
consequently, contractile heart failure [5]. Beneficial effects can be
obtained by increasing blood flow in the fibrotic region to improve the
metabolism of the ischaemic area [6]. Several studies suggest that
MSCs can stimulate the vascularization of the infarcted myocardium
[7–9]. In particular, the MSC-mediated neoangiogenesis results in
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decreased apoptosis of hypertrophied myocytes in the peri-infarct
region, long-term salvage and survival of viable myocardium, reduc-
tion in collagen deposition and sustained improvement in cardiac
function [10]. MSCs have been often grafted in the infarct area either
alone [11, 12] or with scaffolds aimed at limiting their death and
clearance from the site of transplantation [1]. Various biomimetic
polymers, i.e. those based on collagen, matrigel, fibrin, alginate or
other natural fibres, have been already transplanted in models of MI
trying to regenerate the infarcted heart [13]. This study depicts a
method used for the first time because a hyaluronan-based solid
polymer was transplanted in pig hearts to address strategies of cell
therapy and cardiac tissue engineering. Indeed, hyaluronate pos-
sesses many peculiar characteristics that could be useful for cardiac
repairing as: (i) it adheres tenaciously to MSCs because of the spe-
cific interaction with the highly expressed receptor CD44 [14], (ii) its
small fragments which are produced by hyaluronidase and/or chemi-
cal agents are angiogenic [15] and (iii) its ester derivatives can be for-
mulated as knitted scaffolds with elastic properties and resistance to
stretch useful for contractile tissue repair [16, 17].
Campoccia et al. [18] extensively reviewed the key features of the
hyaluronan-based knitted scaffold (HYAFF11) used in this study.
HYAFF11 is derived through the total esterification of sodium hyalur-
onate (80–200 kD) with benzyl alcohol on the free carboxyl groups of
glucuronic acid. Using an aqueous environment, in vitro studies dem-
onstrated that the spontaneous hydrolysis of the ester bonds of HYA-
FF11 requires about 2 months and that the progressive loss of
esterification induces the polymer to become more hydrated and sol-
uble. In contrast, the hyaluronan-ester backbone chain appears to be
more stable than the ester bonds. With respect to cytotoxicity, HYA-
FF11 appears to be a cytocompatible polymer, as proved not only by
the conventional cytotoxicity screening procedures but also by exten-
sive experimentation with many different cell types. HYAFF11 does
not significantly alter the in vitro neutrophil morphology or locomo-
tion, or the level of macrophage metabolic activation as would be
expected with a degrading material. HYAFF11 used in implantation
studies also appears to be an inert polymer, which gives minimal
response in the first month following implantation. A macrophage-
mediated response resulting from polymer degradation is usually
observable after 3 months. However, such a response is mostly con-
fined to the site where the material is implanted. Additional in vivo
studies indicate that the material disappears about 4 months after
implantation. No evidence of toxicity was detected during a 1-year
study following implantation. For tissue engineering applications, the
non-woven structured materials made of HYAFF11 allow good cell
adhesion and viability. An advantage of HYAFF11-based scaffolds is
good cell adhesiveness even in the absence of any coating or surface
conditioning, a treatment that is often required by other widely used
support matrices such as those made of polyglycolic and polylactic.
The total benzyl esters of hyaluronic acid are sufficiently stable in
aqueous solution to allow incubation with cells for over 3 weeks.
Under in vitro cell culture conditions the material maintains its struc-
tural integrity, can be handled easily, and does not contract as some
collagen-based materials do.
Thus, the main purpose of this proof-of-concept study was to
investigate whether the transplantation of autologous MSCs with a
hyaluronan-based knitted scaffold was able to induce neoangiogene-
sis and histological modifications to the infarcted myocardium and
restore the blood perfusion in the fibrous scar.
Materials and methods
Animal preparation and general surgery
All procedures were performed in compliance with the relevant Euro-
pean laws and institutional guidelines and approved by the appropriate
institutional committees. Forty-nine-week-old crossbreed female swine
were stabulated. They weighted about 30 kg, and 8 weeks later, at the
time of euthanasia, they had reached a body weight of approximately
45 kg. Before the surgical procedure, the animals were sedated with
the intramuscular injection of a zolazepam/tiletamine admixture (Zoletil,
Virbac). A double vascular access was then obtained via auricular
veins through two 19G over-the-needle catheters. General anaesthesia
was induced by the slow intravenous administration of propofol (Prop-
ovet, Esteve). The swine were then intubated and anaesthetized with
isoflurane (Isoflo, Abbott) delivered through a circle system. Mechani-
cal ventilation was initiated and maintained throughout the surgical
operation. Analgesia was provided by a continuous intravenous infu-
sion of fentanyl (Fentanest, Pfizer) and lidocaine (Lidocaina 2%, Fort
Dodge), and neuromuscular blockade was obtained by administration
of atracurium besylate (Tracrium, Glaxo Smith Kline). After surgery the
animals were moved to a quiet and warm environment and left to
recover. Analgesia was provided by administering buprenorphine (Tem-
gesic, Schering-Plough) every 6 hrs. Routine antibiotic therapy was
also administered. Before every contrast enhanced ultrasonographic
examination, the animals were sedated as described above and a sin-
gle vascular access obtained. A flow-by method was then used to
administer 100% oxygen. Just after the last ultrasound examination,
the animals were killed: sedation was deepened to total anaesthesia by
the intravenous administration of thiopental (Pentothal Sodium, Inter-
vet). A lethal overdose of potassium chloride was finally given by the
same route.
Isolation and primary expansion of MSCs
With the animal under general anaesthesia, 50 ml of bone marrow
was aspirated from the iliac crest of each pig and then transferred into
50 ml of a-modified Eagle’s medium (a-MEM) containing 20% foetal
bovine serum (FBS), 0.1 lg/ml L-glutamine, 100 U/ml penicillin,
100 U/ml streptomycin and 250 lg/ml amphotericin B. Cells were fil-
tered through a 70 lm nylon filter and plated into a 75 cm2 flask.
They grew in complete a-MEM at 37°C and 5% CO2 for 3 days, then
the medium was replaced and the adherent cells expanded for further
18 days, to reach passage 3. These adherence-selected cells, namely
MSCs, were washed with phosphate-buffered saline (PBS) and
detached by incubation with 0.25% trypsin and 0.1% EDTA for 3 min.
at 37°C. At passage 3, the differential potential of MSCs was not mod-
ified, and the risk of genetic and/or epigenetic abnormalities was not
present [19]. The complete medium was added to inactivate trypsin
activity. MSCs were centrifuged at 450 9 g for 10 min., resuspended
in a complete medium and counted in duplicate using a Burker haemo-
cytometer [20].
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Immunofluorescence detection and flow
cytometry analysis
Mesenchymal stem cells were transferred into 12-well plates, fixed
with 3% paraformaldehyde in PBS at room temperature for 15 min.
and rinsed twice with PBS after blocking with 4% bovine serum albu-
min (BSA) dissolved in 0.2% tween-20/PBS. Primary mouse monoclo-
nal antibodies against pig cross-reacting CD90 (Thy-1), 1:100
(Pharmingen, San Diego, CA, USA), pig CD11 1:50 (Serotec, Oxford,
UK), pig CD31 1:10 (Serotec) and pig mononuclear phagocyte factor
1:50 (MPF, Pharmingen) were used to characterized the pig MSC phe-
notype. The antibodies were diluted in a blocking buffer for 1 hr at
room temperature and washed three times in PBS. The secondary
Cy3-conjugated polyclonal anti-mouse antibody (Sigma-Aldrich, St.
Louis, MO, USA) was diluted 1:2000 in a blocking buffer and washed
three times in PBS. Nuclei were stained with DAPI diluted 1:1000 for
15 min. and washed three times in PBS. The samples were observed
with the IX50-Olympus inverted microscopy (Olympus, Tokyo, Japan).
Negative controls were obtained only with the Cy3-conjugated second-
ary antibody.
The presence of CD90, CD31 and CD11 was then investigated by
flow cytometry analysis using the above-mentioned primary antibodies
and the secondary Cy3-conjugated polyclonal anti-mouse antibody. An
Epics Elite flow cytometer (Beckman Coulter, Fullerton, CA, USA) was
used, equipped with a 15-mW argon ion laser tuned to 488 nm, and
red fluorescence was collected at 605 nm.
Further antigenic and functional features of pig bone marrow MSCs
are described in our previous study [21].
Cell seeding and proliferation on the scaffold
Mesenchymal stem cells were seeded on a squared (3 cm 9
3 cm 9 0.5 mm) HYAFF11 (Fidia Advanced Biopolymers, Abano
Terme, Italy). Before cell seeding, HYAFF11 was incubated for 1 day in
the above-mentioned cell culture medium. The trypan blue exclusion
staining method was used to quantify the adhesion of viable MSCs to
the biopolymer. The number of cells that adhered to the fibres was cal-
culated 24 hrs after cell seeding through a B€urker haemocytometry
chamber, by subtracting the number of cells attached on the well bottom
and those still in suspension from the total amount of seeded cells:
HYAFF adherent cells ¼ total seeded cells well-attached and
suspended cells
Mesenchymal stem cells were seeded at three different densities (0.29,
0.59, 1.09 106 cells/cm2), expanded for 1 week, and the viable MSCs
were identified by fluorescence microscopy through the vital dye carb-
oxyfluorescein diacetate succinimidyl ester (Vybrant CFDASE Cell Tracer
Kit, Molecular Probes, Eugene, Oregon, USA).
The MSC viability within the scaffold was also quantified by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT;
Sigma-Aldrich) as previously reported, assuming the correlation
between MTT concentration and living MSCs [22]. Briefly, the HYA-
FF11/MSCs construct was washed with PBS, transferred into a well
containing 1 ml of MTT solution (1 mg/ml) and incubated for 3 hrs at
37°C. The construct was then put into an Eppendorf tube containing
1 ml of solubilization solution (0.01 M HCl in isopropanol) and vortexed
for 5 min. This provoked the release of MTT whose concentration in the
reduced form was representative of the amount of viable cells. The
samples were centrifuged at 15,000 9 g for 5 min. and the level of the
reduced MTT in the supernatants was read at 595 nm using a multiwell
spectrophotometer (Victor 2 microplate reader, Perkin Elmer, Wellesley,
MA, USA). Then, the viable MSCs cultured within the biomaterial were
quantified using a calibration curve relating known amounts of MSCs,
grown on HYAFF11 at different densities, with the corresponding MTT
values.
To identify the engrafted MSCs in the recipient myocardium, the
MSCs were labelled with 0.4% bromodeoxyuridine (BrdU; Pharmingen)
3 days before transplantation.
The MSCs adhering to the scaffold were also investigated with regard
to their ability to produce VEGF compared with the MSCs grown on
plastic or in suspension. The concentration of the released VEGF was
measured 3 days after cell seeding using an ELISA kit (PeproTech,
Rocky Hill, NJ, USA) and revealed by the Victor 2 multiwell spectropho-
tometer.
Scanning electron microscopy (SEM)
Mesenchymal stem cells cultured on HYAFF11 were processed for
SEM 7 days after cell seeding. Following fixation, the samples were
dehydrated, critical point dried, mounted on aluminium stubs and then
coated with a thin layer of gold using a sputtering device. The samples
were observed in a Philips 505 scanning electron microscope at 10 kV
[23].
Groups of graft transplantation
The swine were comprised into five groups:
(1) Untreated infarct hearts (Ctr infarcted group; n = 7).
(2) HYAFF11 grafted in the infarcted hearts (HYAFF11 group;
n = 6).
(3) MSCs grafted in the infarcted hearts (MSCs group; n = 6).
(4) HYAFF11 + MSCs grafted in the infarcted hearts (HYAFF11/MSCs
group; n = 6).
(5) Untreated non-infarct hearts (Ctr non-infarcted group; n = 5).
Model of myocardial infarction
A first operation was performed through a left thoracotomy at the fourth
to fifth intercostal space. The animal was placed on right lateral decubitus.
Complete antisepsis was performed and a sterile surgical field was placed.
A wide incision was performed and all muscle layers dissected. Once the
pleural space was open, the left lung was gently excluded by compression
to expose the pericardial sac. Pericardiotomy was achieved and lateral
surface of the heart perfectly visualized. Then, the apex of the heart was
gently exposed. The heart was progressively lifted with the interposition
of wet gauzes. The permanent occlusion of the left anterior descending
(LAD) coronary artery and its diagonal branch was preceded by ischaemic
preconditioning. The arteries were intermittently legated with a tourniquet
and alternated with progressively shorter periods of reperfusion, until their
occlusion was definitive. Before the thorax closure, to reduce adhesions,
we applied topically cortisone and a Covidien VascusealTM, a synthetic and
flexible sealant. After previous positioning of a drain, the thorax was
closed. The animal was awakened and closely monitored for 24 hrs.
Four weeks after coronary ligation a second operation was performed
to implant the graft. To avoid the adhesions provoked during the first
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operation, the second operation was performed with a right thoracot-
omy. MSCs were given by intramyocardial injections using a syringe,
whereas HYAFF11 or HYAFF11 plus MSCs were grafted into a sub-
epicardial pocket. In the groups treated with cells (MSCs and HYA-
FF11/MSCs groups), we used autologous MSCs; hence, each pig
received its own MSCs. For a better comparison with the effects caused
by the transplantation of HYAFF11, which covered most of the infarct
region, MSCs were injected into the infarct zone rather than along the
border zone.
The scaffold, with or without MSCs, was positioned inside the pocket
and the myocardial flap closed and fixed above. We preferred to put the
scaffold into an epicardial pocket rather than on the ventricular surface
to avoid the laceration of the edge of the patch and related supported
MSCs, which could result from the use of suture stitching. Moreover,
by grafting the construct into a pouch it was not exposed to the atmo-
sphere of the thoracic cavity as this could lead to dryness and early
death of the cells. Just after the first and second operation, the animals
were treated with amoxicillina depot (Neo Vet-Cillin LA), BUP (bupr-
enorfina, Temgesic) and with amoxicillina, clavulanic acid (Synulox)
and enrofloxacine (Baytril) for an additional 5 days. The animals were
killed 8 weeks after the coronary ligation.
In the pigs subjected to myocardial infarction, the mortality was 35%
and was equally distributed in each group of graft transplantation.
Contrast-enhanced ultrasound echography (CEUS)
Contrast-enhanced ultrasound echography is a non-invasive imaging
technique for quantifying tissue perfusion with microbubble contrast
agents. Microbubbles of sulphur esafluoride (SonoVue, Bracco, Italy)
were suspended in an isotonic solution with a viscosity similar to that
of plasma [24]. The average diameter of the microbubbles was 2.5 lm
to allow the contrast agent to overcome the lung barrier and to dim the
healthy left ventricle in a uniform manner. In humans, this analysis has
proved to be effective for the study of myocardial perfusion [25]. A
good correlation between the blood flow measured by CEUS and a gold
standard, such as microspheres, was demonstrated [26]. A bolus
(5 ml) of the contrast agent was injected into the femoral vein and the
cardiac perfusion analysed after a few minutes. The region of interest
(ROI) was drawn in the third part of the left ventricle, and included the
cardiac apex. The ischaemic area was recognized as a less perfused
region relative to the opposite region, which was closer to the base of
the heart. The echo-contrast images of the heart were video-recorded
several times for 1 min. each and then analysed by dedicated software
(Qontrast 4.00; Esaote, Florence, Italy). The levels of signal intensity
were measured and plotted as diagrams in 1 min. periods and used to
study the rate of myocardial perfusion.
Histochemistry and immunohistochemistry
Eight weeks after coronary ligation, the hearts were blocked in dias-
tole with a solution of 15% KCl and rapidly excised. Cardiac cavities
were rinsed with PBS to remove blood and clots. Then the hearts
were fixed with 10% formalin for 24 hrs and cut into three gross
pieces: apex, middle portion and base that were fixed in formalin for
additional 72 hrs and then subjected to final sampling. Tissue sam-
ples were dehydrated at increasing alcohol concentrations, and
embedded in paraffin. Five-lm-thick serial sections were stained with
haematoxylin and eosin, Sirius Red and Alcian Blue at pH 2.5 along
Fig. 1 Flow cytometry analysis of pig MSC superficial antigens. Flow cytometry analysis shows that pig bone marrow mononuclear adherent cells
stained negative for CD31 and CD11, which are markers of endothelial cells and monocytes/macrophages respectively. On the contrary, most cells
stained positive for CD90, a superficial antigen that is detectable in MSCs. The negative control was obtained using the Cy3-conjugated antibody in
the absence of the primary antibody.
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with periodic acid-Schiff (PAS) to assess, respectively, cardiac tissue
morphology, extracellular matrix collagen and glycosaminoglycan
deposition. Additional 5-lm-thick tissue sections were used for immu-
nohistochemistry. Endogenous peroxidase activity was blocked with
3% H2O2 for 10 min. at room temperature and the antigens retrieved
in a microwave for 10 min. at full power in a 10 mM citrate buffer,
pH 6.0. Non-specific bindings were blocked with 10% goat serum for
45 min. Then, the slides were incubated with the primary mouse
monoclonal antibody anti-BrdU (BioGenex, San Ramon, CA, USA), or
anti–von Willebrand Factor (vWF, 1:200, Abcam, Cambridge, UK), or
anti-CD3 (1:100; NeoMarker, Fremont, CA, USA) and identified by the
NovoLinkTM Polymer Detection System procedure (Novocastra, New
Castle, UK) according to the manufacturer’s instructions. The circular/
oval structures lined by vWF+ cells were identified as capillaries when
their diameter was less than 20 lm; they were considered to be arte-
rioles or venules (medium-sized vessels) when wider than 20 lm.
The diameter of oval vessels was calculated as the half sum between
the largest and the shortest dimension. To obtain the values of vas-
cular density per area unit (0.33 mm2), both capillaries and medium-
sized vessels were separately counted in six different fields of the
sections that showed the highest vessel density. To quantify the
inflammatory response per area unit (0.33 mm2), the intensity stain-
ing of CD3-positive cells was counted in ten different fields of the
sections from the border zone. Image-Pro Plus software (Media
Cybernetics, www.mediacy.com) was employed to perform counts and
density calculations.
A D
E F
B
C
Fig. 2Morphological analysis and viability of MSCs seeded on HYAFF11. The hyaluronan-based scaffold was analysed by SEM which revealed (a)
the regular texture of HYAFF11 without MSCs (white bar, 1 mm), (b) the adhesion of MSCs 1 week after seeding (white bar, 1 mm) and (c) their
expansion on the fibres (white bar, 0.1 mm). Different MSC densities of seeding (0.29, 0.59, 1.09 106 cells/cm2) were initially tested to evaluate
the best yield of cell adhesion and proliferation on HYAFF11 (d). 1 9 106 cells/cm2 gave the highest proliferation response evaluated by MTT anal-
ysis (each value represents the mean  SEM of three separate experiments) and expressed as absolute number of viable MSCs. CFDA-loaded MSCs
cultured on HYAFF11 at the three different densities were also evaluated 1 week after seeding (right images; magnification = 1009;
bar = 100 lm). Analysis also revealed (e) that MSCs cultured for 3 days on HYAFF11 were about four times more viable than those grown in sus-
pension (P < 0.01). These last values are expressed as mean percentage  SEM (n = 3) of the viable MSCs with respect to those cultured on a
plastic dish (100%). Finally, (f) the scaffold had a square-shaped appearance.
522 ª 2013 The Authors
Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Statistical analysis
Quantitative data are expressed as mean  SEM. Except for the Peak/
TTP data, which were analysed by the paired Student’s t test, statistical
analysis between two groups was performed by the unpaired Student’s
t test. Analysis between three or more groups was performed by one-
way ANOVA, followed by Tukey’s test for comparisons between groups. A
value of P  0.05 was considered statistically significant.
Results
Characterization, adhesion and viability of MSCs
grown on HYAFF11
Observation at the fluorescence microscopy (image not shown)
revealed that MSCs stained negative for CD11, CD31 and MPF, while
they expressed CD90, a superficial molecule present in MSCs that
have been isolated from different animal species, including pigs [27,
28]. These results were confirmed by flow cytometry analysis
(Fig. 1).
Scanning electron microscopy revealed the regular knitted texture
of HYAFF11 (Fig. 2a) and the strong adhesion of MSCs to the hyal-
uronan fibres embedded in a dense extracellular matrix (Fig. 2b and
c). Three different densities (0.29, 0.59, 1.09 106 cells/cm2) were
checked for MSC seeding on HYAFF11. The highest yield (94.5%)
was obtained with 1.0 9 106 cells/cm2, whereas 0.29 and 0.59 gave
a cell recovery of 82.0% and 84.5%, respectively. The corresponding
cell viability and 1-week expansion on HYAFF11 of CFDA-loaded
MSCs at these three different densities are shown in Figure 2d. The
best condition was obtained with the highest cell density which was
chosen for transplantation to the infarct area. Using MTT analysis, the
lowest cell density was used to compare the viability of the MSCs
adhering to the fibres of HYAFF11 with that of the MSCs in suspen-
sion. Figure 2e shows that MSCs cultured on HYAFF11 for 3 days
were about four times more viable than the same amount of cells
grown in suspension (P < 0.01), suggesting that the process of
anoikosis can be significantly blunted by growing MSCs onto this
scaffold.
The macroscopic square-shaped appearance of HYAFF11 is
shown in Figure 2f. In the HYAFF11/MSCs group, the cells covered
all the surface of the polymer (image not shown). Figure 3 shows the
morphology of the HYAFF11 fibres transplanted in the infarct area in
both HYAFF11 and HYAFF11/MSCs groups.
The ability of MSCs to produce VEGF when supported by the hyal-
uronan-based fibres was also investigated. The amount of VEGF
released under this condition was similar and not significantly differ-
ent from that produced by the MSCs seeded on the plastic dish
(P = 0.182) or suspended in their culture medium (P = 0.06). The
concentrations of the released VEGF were as follows (pg/ml, n = 4):
690.6  119.7, 655.7  102.4 and 549.6  72.1 respectively (data
not shown).
Blood perfusion of the infarcted heart
The CEUS of the heart (Fig. 4 and Supporting Information) allowed
the evaluation of the perfusion of the infarct region. The following
parameters were determined by Qontrast software (Fig. 4c):
(i) the peak per cent (Peak), which represents the highest value
of perfusion monitored for 1 min.;
A B
C D
Fig. 3Morphology of HYAFF11 fibres
transplanted in the infarct area. The con-
tour of the HYAFF11 fibres from both
HYAFF11 and HYAFF11/MSCs groups
is oval or lengthened, according to the
direction of the mesh. These samples
were obtained 4 weeks after transplanta-
tion and were stained with haematoxylin
and eosin. Scale bars: (a and b) 100 lm;
(c and d) 50 lm.
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(ii) the time to peak (TTP), which is the time (sec.) lasting from
the beginning of the CEUS to the achievement of the peak;
(iii) the regional blood volume (RBV), which corresponds to the
blood volume monitored for 1 min.;
(iv) the regional blood flow (RBF), which corresponds to the
blood flow monitored for 1 min.
Through a further elaboration of these parameters, one more index
was considered the ratio between %Peak and TTP (Peak/TTP). This
was very effective for evaluating the degree of perfusion of the inves-
tigated cardiac region because it strictly correlated (P < 0.01) with
either RBV or RBF (Fig. 4d). Figure 2e shows the Peak/TTP ratio cal-
culated under the different experimental conditions by comparing the
values obtained 4 weeks after coronary ligation (just before graft
transplantation) with those obtained in the same pig 8 weeks after
coronary ligation. The Peak/TTP ratio did not significantly change in
the untreated infarcted group or the HYAFF11 and MSCs groups,
but it increased about twofold in the HYAFF11/MSCs group
(P = 0.05). Moreover, the Peak/TTP ratio of the HYAFF11/MSCs
group was comparable with that of non-infarcted, healthy swine mea-
sured in the same region of the heart.
A
C
D E
B
Fig. 4 CEUS of the infarcted heart. (a) The
figure shows the scaffold during its
engraftment inside a pouch created by
elevating a superficial flap of the epicar-
dium of the infarcted area (yellow circle),
4 weeks after the coronary ligation. The
scaffold was put on the centre of the
infarct region, covering more than 50% of
this area. (b) The blood flow was visual-
ized by coloured tones fading from red to
blue, corresponding to areas of high and
low perfusion respectively. (c) The figure
shows a representative slope of the 1-
min. passage of the high-density particles
through the elective area of investigation
in a non-infarcted pig heart. (d) The ratio
between Peak and TTP (Peak/TTP) posi-
tively correlated either with RBV or RBF
(P < 0.01, n = 10). (e) The bar graph
compares the Peak/TTP ratio measured
4 weeks after coronary ligation just before
grafting with that obtained in the same
pig 8 weeks after coronary ligation. Peak/
TTP did not significantly change in the
groups tested with the exception of the
HYAFF11/MSCs group whose value at
week 8 was about two times that at week
4 (P = 0.05). The Peak/TTP ratio of the
HYAFF11/MSCs group was the same of
that measured in a healthy pig of the
same strain and weight 8 weeks after sta-
bulation. Ctr infarcted, n = 5; HYAFF11,
n = 3; MSCs, n = 3; HYAFF11/MSCs,
n = 3; Ctr non-infarcted, n = 5.
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In vivo tracking of BrdU-labelled MSCs
Four weeks after grafting, BrdU+ MSCs were mainly identified in the
infarct area and in the border zone of both MSCs and HYAFF11/
MSCs groups (Fig. 5), whereas very few BrdU+ MSCs moved to the
healthy remote regions of the heart (image not shown). Many labelled
MSCs were localized near the vessels structures (Fig. 5, black
arrows) and inside the vessel wall (Fig. 5, white arrows).
Vessel density
Blood vessels were identified in the infarct region as circular/oval
structures lined by one or more vWF+ cells (Fig. 6a). The number of
medium-sized vessels was significantly increased in the HYAFF11
group relative to the MSCs group (P < 0.05; Fig. 6b). The number of
capillaries and total vessels (capillaries + medium-sized vessels) was
apparently increased in both groups treated with HYAFF-11, but this
number did not reach statistical significance with respect to the
untreated infarct group.
Inflammatory reaction
The degree of the inflammation process was expressed either as
number of infiltrated cells (Fig. 7b) or as the area stained with CD3-
positive inflammatory cells (Fig. 7a). Using both criteria, the hearts of
the HYAFF11 group showed an overall degree of inflammation simi-
lar to that of the untreated infarct group. The score of both the HYA-
FF11 and HYAFF11/MSCs groups was calculated taking the foreign
body reaction that was bordered only on the fibres of the scaffold
(Fig. 7c and d) into account. The transplantation of MSCs, with or
without HYAFF11, almost completely reduced the infarction-depen-
dent cellular infiltrate (Fig. 7a and b), confirming the notion that
MSCs can exert an important immunosuppressive action.
Extracellular matrix and cardiomyocyte
morphology
At the border zone, fibrosis was characterized using the highly hydro-
phylic Sirius Red dye that stains collagen I and III fibres; as seen in
Figure 8, the HYAFF11 and HYAFF11/MSCs groups showed the
lesser amount of red stained collagen when compared with the MSCs
and untreated infarct groups. After Alcian Pas staining on sections
from the same areas the HYAFF11/MSCs group showed an intensely
alcianophilic extracellular matrix. In the corresponding haematoxylin
and eosin stained sections, morphological changes were seen in car-
diomyocyte facing the fibrotic scar. Although cardiomyocyte hyper-
trophy was not observed, vacuolization and degeneration of cardiac
cells was a finding in all the investigated groups even though the HY-
AFF11/MSCs group was less affected.
Discussion
This study illustrates the effectiveness of restoring blood perfusion in
the fibrous region of the infarcted myocardium after transplantation
of autologous MSCs with a hyaluronan-based scaffold. The myocar-
dial perfusion in pigs was analysed using CEUS. The most sensitive
parameter used was the Peak/TTP ratio because it correlated with
both RBV and RBF. This index was restored only in the infarct region
of the hearts treated with the complete construct HYAFF11/MSCs,
doubling the value detected in the same pig before transplantation.
A B
C D
Fig. 5 Localization of BrdU-labelled MSCs.
In the myocardial preparations, the dark
brown elements identified the nuclei of
MSCs pre-loaded with BrdU before
implantation. (a) BrdU-labelled MSCs were
mainly present in the infarct region and in
the border zone (dotted line), whereas few
of them moved to the healthy remote
regions of the heart (data not shown). (b–
d) Many BrdU+MSCs were localized at the
level of vessels structures, just near them
(black arrows), or inside the vessel wall
(white arrows). Scale bars: (a and b)
25 lm, (c and d) 10 lm.
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The Peak/TTP ratio of the infarct area of the HYAFF11/MSCs group
was even comparable with that of the non-infarcted healthy animals.
To assess the degree of vascularization induced by the different treat-
ments scheduled in this study, both capillary and medium-sized ves-
sel densities were measured in the infarct area of the explanted
hearts. In the HYAFF11 group the number of medium-sized vessels
was increased compared with the MSCs group, whereas no statistical
difference was observed between the other groups. To explain why
blood perfusion increased in the HYAFF11/MSCs group with respect
to the other groups in the presence of similar amount of vessels, we
suggest that in this scaffold-cell construct MSCs have synergically
contributed to improving blood flow by blunting inflammation thereby
decreasing the oedema-dependent compression exerted on the small/
medium vessels. Moreover, it should be taken into account that the
in vitro viability of the MSCs adhering to the scaffold was higher than
that of MSCs in suspension, which supports the hypothesis that a
higher number of MSCs can survive ischaemic stress when attached
to HYAFF11 rather than injected alone. In addition, the MSCs ability
to produce VEGF, one of the most powerful angiogenic factors, was
not precluded by their adhesion to HYAFF11.
On the other hand, the mechanism by which HYAFF11
increased the vessel density could be related to the gradual frag-
mentation of its fibres into small-sized hyaluronate oligosaccharides
[15]. Indeed, hyaluronan with 6–10 residues has been described as:
(i) promoting the proliferation of HUVEC, (ii) inducing angiogenesis
in the chicken chorioallantoic membrane assay and (iii) increasing
VEGF mRNA levels in HUVEC [29]. In our condition, the localized
foreign inflammatory reaction around the fibres of HYAFF11 could
A
B
Fig. 6 Vascularization of the infarct area. (a) The blood vessels were identified in the infarct region as circular/oval structures stained with vWF as
indicated by the arrows (upper bars, 50 lm; lower bars, 25 lm). (b) The quantitative analysis was performed with all the representative regions of
the infarct area (both centre region and border zone). In the bar graph, the number of total vessels corresponds to the sum of capillaries and med-
ium-sized vessels. The number of medium-sized vessels significantly increased in the HYAFF11 group with respect to the MSCs group (P < 0.05).
Ctr infarcted, n = 5; HYAFF11, n = 3; MSCs, n = 3; HYAFF11/MSCs, n = 4.
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have contributed to the acceleration of the breakdown of hyaluronan
into smaller fragments. It has also been documented that HYA-
FF11, when soaked in a physiological solution and in the absence
of hydrolytic enzymes, releases about 90% of its benzyl alcohol
within 20 days [16]. This data support the hypothesis that a number
of fibres could be already fragmented 4 weeks after scaffold trans-
plantation in in vivo conditions, despite the initial resistance of HYA-
FF11 to hyaluronidase degradation [16]. These small hyaluronan
oligomers are able to activate vascular endothelial cells through the
CD44 and RHAMM receptors which, in turn, stimulate the ERK-
dependent angiogenic process [30].
Although we did not observe any consistent increase in the Peak/
TTP ratio in the MSCs group, positive effects on blood perfusion after
the injection of bone marrow MSCs in the infarcted area of the pig
heart, without any polymeric support, have been reported by other
investigators [31–33]. In our study, the lack of improvement in blood
flow after the transplantation of MSCs only could result from differ-
ences in experimental protocols. For instance, rather than grafting
MSCs soon after the induction, we waited 4 weeks to avoid the acute
phase of the inflammatory response, to decrease the risk of arrhyth-
mias and to await the formation of the scar. Autologous MSCs were
also injected by Liu et al. in a swine model of cardiac infarction, leading
A
B
C D
Fig. 7 Inflammatory reaction and related
score of the infarct area. (a) The micro-
graphs show the inflammation process
expressed as area stained with CD3-posi-
tive inflammatory cells (lymphocytes),
whereas the bar graph shows the statisti-
cal difference among groups. The trans-
plantation of MSCs, with or without
HYAFF11, almost completely reduced the
density of cellular infiltrate. Scale bars:
100 lm. *P < 0.05 versus both Ctr
infarcted and HYAFF11 groups. (b) The
quantification of the inflammatory reaction
was confirmed by attributing a score from
0 to 2, according to the degree of cell
infiltration (table inside). (c and d) A for-
eign body reaction was clearly activated
close to the fibres of HYAFF11 (black
arrows) 4 weeks after transplantation.
Scale bars: (c) 100 lm; (d) 50 lm. Mac-
rophages and giant cells were found only
around the fibres of the scaffold (red
arrows). Ctr infarcted, n = 5; HYAFF11,
n = 3; MSCs, n = 3; HYAFF11/MSCs,
n = 4.
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to an increase in vessel density [27]. Again, we suppose that this find-
ing seems to contrast the absence of neovascularization observed in
our MSCs group because the induction of MI was substantially differ-
ent. In the infarction model of Liu et al., the coronary ligation was fol-
lowed by reperfusion and MSCs were injected just after reperfusion.
Moreover, vessel density was assessed a short period of time after
grafting and no inherent information was given 4 weeks after cell injec-
tion. Moreover, in that study, the data concerning myocardial perfusion
were not provided; therefore, we cannot conclude that the increased
vascularization was really effective in enhancing regional blood flow.
In our study, the biocompatibility of HYAFF11 in the infarct
region of the heart was also satisfactory, as already demonstrated in
other tissues [16]. Indeed, despite a typical foreign body reaction that
was confined to the hyaluronan fibres, an amount of infiltrated cells,
including CD3-positive lymphocytes, comparable with that observed
in the untreated infarcted group were found in the remaining myocar-
dial region. That the presence of MSCs in the construct attenuated
this inflammatory response is probably owing to their innate immuno-
suppressive properties [34].
Apart from the inflammatory response, the native tissue positively
interacted with the HYAFF11/MSCs construct modifying the extra-
cellular matrix with a reduced presence of collagene and increased
amount of proteoglycans. The border-zone cardiomyocytes also
reacted favourably to the graft as a lower degree of cellular damage
was found.
In conclusion, these findings demonstrate that in the scar follow-
ing a myocardial infarction the transplantation of autologous bone
marrow MSCs with a hyaluronan-based knitted scaffold completely
Fig. 8 Extracellular matrix and cardiomyocyte morphology. Micrographs are representative of the border zone of the infarct area. The HYAFF11 and
HYAFF11/MSCs groups showed the lesser amount of collagen types I and III (Sirius Red), corresponding to a reduced fibrosis, when compared
with the MSCs and untreated infarct groups (scale bar, 100 lm). The HYAFF11/MSCs group showed also the highest presence of proteoglycans in
the extracellular matrix (Alcian Blue) with respect to the other groups (scale bar, 100 lm). Although nearby the fibrotic area vacuolization and
degeneration of cardiac cells (arrows) were present in all the groups (Haematoxylin and Eosin), this finding was attenuated in the HYAFF11/MSCs
group (scale bar, 50 lm).
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restores blood perfusion and strongly attenuates the inflammation
process. These positive effects are superior to those obtained by
grafting MSCs alone or the scaffold itself.
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